What Jeil Pharmaceutical does

Jeil Pharmaceutical Co. Ltd. is a South Korea-based, mid-sized pharmaceutical company headquartered in Seoul that develops proprietary small-molecule drug candidates for metabolic, inflammatory, and neurological disorders. According to available sources, the company was founded in 1969 and employs between 501 and 1,000 staff, although no detailed company history or milestone timeline was disclosed in the source data.

The company's pipeline centers on two differentiated assets: (1) JP-2266, a dual SGLT1/2 inhibitor in Phase II clinical trials as of 2025, with stated potential applications in type 2 diabetes, chronic kidney disease, heart failure, obesity, MASH (metabolic dysfunction-associated steatohepatitis), and PCOS; and (2) patented dihydrothiopyranopyrimidine compounds acting as phosphodiesterase PDE4 inhibitors, granted as IP for treating inflammatory joint disease and neurological disorders. Jeil also operates a digital portal branded "Eagleye," accessible via a login page on the corporate website, whose specific functional purpose is not disclosed.

The business model is grounded in proprietary drug development and patent-protected therapeutics; pricing is not publicly disclosed and there is no information on revenue mechanics, go-to-market structure, distribution channels, or named customers. Ownership, institutional investor base, and detailed financial line items are not fully substantiated in the source data, with the firmographic record indicating a private company while the financial table lists multi-year line-item financials (interpreted as Korean Won), suggesting either listing status ambiguity or data-source overlap with a related entity.

Name

Jeil Pharmaceutical

Legal name

Jeil Pharmaceutical Co. Ltd.

Website

https://jeilpharm.co.kr

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Jeil Pharmaceutical is a Seoul-based, mid-sized Korean pharmaceutical company developing proprietary small-molecule drug candidates, including the Phase II SGLT1/2 inhibitor JP-2266 for metabolic disorders and patented PDE4 inhibitors for inflammatory and neurological diseases.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Pharmaceutical drug development
• SGLT1/2 inhibitors
• PDE4 inhibitors
• Metabolic disease therapeutics
• Anti-inflammatory treatments

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Jeil Pharmaceutical is a Korean pharmaceutical company engaged in drug development, with an active pipeline that includes JP-2266, a dual SGLT1/2 inhibitor in Phase II clinical trials targeting metabolic conditions such as type 2 diabetes, chronic kidney disease, heart failure, obesity, MASH, and PCOS, as well as patented dihydrothiopyranopyrimidine compounds acting as phosphodiesterase PDE4 inhibitors for treating inflammatory joint disease and neurological disorders.

Product overview

Jeil Pharmaceutical operates as a pharmaceutical company with an active drug development pipeline spanning metabolic therapies and anti-inflammatory treatments. The company's pipeline includes JP-2266, a dual SGLT1/2 inhibitor currently in Phase II clinical trials, and patented dihydrothiopyranopyrimidine PDE4 inhibitor compounds for inflammatory joint disease and neurological disorders. The company also maintains a digital platform called Eagleye.

Differentiator

Problem solved

Functional benefit

Brands

• Eagleye: Brand or product name referenced on the company's website login page

Products and services

• JP-2266 A dual SGLT1/2 inhibitor drug candidate in Phase II clinical trials, being developed for potential therapeutic applications in metabolic conditions including type 2 diabetes, chronic kidney disease, heart failure, obesity, MASH (metabolic dysfunction-associated steatohepatitis), and PCOS.
• Dihydrothiopyranopyrimidine PDE4 Inhibitors Patented phosphodiesterase PDE4 inhibitor compounds developed as drug candidates for treating inflammatory joint disease and neurological disorders. The patented dihydrothiopyranopyrimidine compounds represent exclusive intellectual property in the inflammatory and neurological disorder treatment space.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Expansion highlights4 records

Broad incumbents

• Amgen: Large biopharma with a meaningful cardiometabolic and inflammation franchise including Repatha and Tezspire. Comparable to Jeil as a potential acquirer/partner with relevant therapeutic overlap.
• Eli Lilly: Leader in obesity/MASH via tirzepatide, with major metabolic franchise overlap with Jeil's JP-2266 pipeline. Lilly sets the commercial bar in obesity and is a probable strategic partner for advanced metabolic assets.
• GSK: Has a leading PDE4 franchise through roflumilast and other PDE4 assets, directly comparable to Jeil's granted PDE4 inhibitor IP. A natural licensing target or strategic competitor in inflammatory/neurological PDE4 space.
• Boehringer Ingelheim: Co-developer of Jardiance (empagliflozin) with Eli Lilly, an SGLT2 inhibitor with broad cardiometabolic and renal indications. Directly comparable to JP-2266's lead target indications.
• AstraZeneca: SGLT2 leader with Farxiga approved across T2D, CKD, and heart failure — the same core indications JP-2266 targets. AZ is the dominant benchmark competitor and a likely potential partner/acquirer in the cardiometabolic space.

Direct peers

• Yuhan Corporation: One of the largest Korean pharmaceutical firms with both branded products and a development pipeline in metabolic and chronic disease areas. Comparable to Jeil on therapeutic categories and Korea-centric operations.
• Dong-A ST: Mid-cap Korean pharmaceutical firm with branded and pipeline assets in metabolic and specialty areas; comparable to Jeil in size, Korea-centric operations, and therapeutic ambition.
• Daewoong Pharmaceutical: Korean specialty pharma with branded products and pipeline efforts in metabolic and inflammatory disease, similar in scale and therapeutic orientation to Jeil Pharmaceutical.
• Hanmi Pharmaceutical: Mid-sized Korean pharmaceutical company with a pipeline spanning metabolic disease and inflammation, comparable to Jeil in size, geography, and therapeutic focus. Hanmi is a useful direct comp for Korean specialty pharma R&D strategy.

Emerging players

• Madrigal Pharmaceuticals: Specialty biotech with resmetirom, the first FDA-approved MASH therapy. Directly comparable to JP-2266's MASH indication as a focused competitor with regulatory first-mover advantage in that sub-segment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jeil Pharmaceutical